This book is open access under a CC BY 4.0 license. This quick-reference handbook offers a concise and practical review of key aspects of the treatment of ST-segment elevation myocardial infarction (STEMI) in the era of primary percutaneous coronary intervention (PPCI). In the context of STEMI, PPCI is the preferred mode of emergency revascularization. Access to PPCI is rapidly increasing and is now routinely practiced in both general and specialist hospitals and there has been a recent emphasis on developing STEMI networks to enhance and expedite the referral pathway. This coupled with concurrent developments to enhance the safety and efficacy of the PPCI procedure has heralded an era where STEMI interventions are increasingly considered an important subspecialty within interventional cardiology. Written by leading cardiologists who have been instrumental in the adoption of PPCI in their respective institutions, the book provides junior and senior cardiologists alike with insightful and thought-provoking tips and tricks to enhance the success of PPCI procedures, which may in turn translate into direct improvements in outcomes. The book is also relevant for healthcare providers and emergency department physicians.

In Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease, the major investigators working in this rapidly advancing field join together under the aegis of A. Michael Lincoff and Eric J. Topol to provide the first comprehensive overview of the preclinical and clinical development of the glycoprotein IIb/IIIa receptor antagonists. These acknowledged experts elucidate the theoretical basis for the inhibition of platelet aggregation in the treatment of coronary syndromes, present and synthesize evidence for the efficacy of glycoprotein IIb/IIIa blockade in inhibiting ischemic complications of both coronary intervention and acute coronary syndromes, and provide guidelines for the use of this novel class of agents in the clinical management of cardiovascular disease. They also compare the pharmacology and clinical efficacy of the currently available glycoprotein IIb/IIIa receptor inhibitors and speculate about further potential applications of these agents in the treatment of vascular disease. Written by the scientists and physicians who discovered and characterized this important new class of receptors, invented the first IIb/IIIa agents, and conducted the definitive clinical trials, Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease offers the most complete and authoritative review of these powerful new therapeutics available today.

New updated edition first published with Cambridge University Press. This new edition includes 29 chapters on topics as diverse as pathophysiology of atherosclerosis, vascular haemodynamics, haemostasis, thrombophilia and post-amputation pain syndromes.

Cardiovascular Thrombus: From Pathology and Clinical Presentations to Imaging, Pharmacotherapy and Interventions provides a comprehensive, up-to-date presentation of the research and clinical practices as related to the contemporary aspects of the diagnosis and management of cardiovascular thrombosis. The formation, identification and management of cardiovascular thrombus is of paramount importance for researchers and practicing physicians, yet it remains one of the most challenging diagnostic and clinical scenarios. This important reference connects between research, up-to-date clinical knowledge, and the technological tools available for diagnosis and management of thrombus in cardiovascular medicine. The book includes comprehensive descriptions and review of pathology, clinical presentations, diagnosis, pharmacotherapy, interventions and future trends. It is the perfect reference for basic science students and researchers in general and interventional cardiology, general and interventional radiology, vascular medicine specialists, and vascular, general and cardiac surgeons. Provides comprehensive presentation of the pathophysiology, clinical presentations and diagnosis of cardiovascular thrombosis Includes the most up-to-date information on the practical management of patients with thrombus related conditions Written by the leading experts in the field Describes the current and upcoming pharmacotherapy and technology available for thrombus research and treatment

The establishment of precise and reliable biomarker tests for the early stages of cardiovascular disease is of great importance and can be the cornerstone in the prevention of future cardiovascular disease (CVD). Furthermore, some biomarkers may provide important information concerning the pathogenesis of CVD or appear to be useful in risk stratification, in CVD diagnosis, or in monitoring therapy; many others may be risk factors themselves, representing therefore potential targets of therapy. The ideal biomarker should have the following characteristics: highly sensitive, specific, reliable, accessible, standardized, dependable, cost effective, and easily interpretable by clinicians. The present book focuses on the presentation and evaluation of the most promising classical and novel biochemical markers used in CVD (coronary artery disease, hypertension, heart failure, hyperlipidemia, peripheral arterial disease). The underlying pathophysiological characteristics of each biomarker, as well as potential clinical implications in daily practice are reviewed in this book.

With authoritative coverage of everything from recent discoveries in the field of vascular biology to recent clinical trials and evidence-based treatment strategies, Vascular Medicine, 3rd Edition, is your go-to resource for improving your patients' cardiovascular health. Part of the Braunwald family of renowned cardiology references, this updated volume integrates a contemporary understanding of vascular biology with a thorough review of clinical vascular diseases, making it an ideal reference for vascular medicine specialists, general cardiologists, interventional cardiologists, vascular surgeons, and interventional radiologists. - Incorporates technologic advances in vascular imaging – including ultrasound, MRI, CTA, and catheter-based angiography – along with more than 230 new figures, providing an up-to-date and complete view of the vascular system and vascular diseases. - Covers novel antithrombotic therapies for peripheral artery disease and venous thromboemboism, advances in endovascular interventions for aortic aneurysms, and today's best surgical treatments for vascular diseases. - Includes seven new chapters: Pathobiology of Aortic Aneurysms; Pathobiology and Assessment of Cardiovascular Fibrosis; Large Vessel Vasculitis; Medium and Small Vessel Vasculitis; Epidemiology and Prognosis of Venous Thromboembolic Disease; Fibromuscular Dysplasia; and Dermatologic Manifestations of Vascular Disease. - Discusses methods for aggressive patient management and disease prevention to ensure minimal risk of further cardiovascular problems. - Keeps you current with ACC/AHA and ECC guidelines and the best ways to implement them in clinical practice. - Enhanced eBook version included with purchase, which allows you to access all of the text, figures, and references from the book on a variety of devices